Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Tomizawa, Daisuke  [Clear All Filters]
2024
Fujimori K, Ikenobe N, Gocho Y, Uchiyama T, Deguchi T, Sakaguchi H, Tomizawa D, Takeuchi I, Shimizu H, Arai K, et al. Hematopoietic stem cell transplantation in two sisters with bone marrow failure associated with POLE gene variants. Pediatr Blood Cancer. 2024:e30919.
Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, Koh K, Koga Y, Yoshida N, Sato M, et al. A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia. J Hematol Oncol. 2024;17(1):24.
Iguchi A, Uchiyama T, Fujimori K, Gocho Y, Sakaguchi H, Deguchi T, Tomizawa D, Imadome K-I, Onodera M, Matsumoto K. HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia. Int J Hematol. 2024.
van Weelderen RElise, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, et al. Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Blood Adv. 2024.
2023
Aoki T, Shiba N, Tsujimoto S, Yamato G, Hara Y, Kato S, Yoshida K, Ogawa S, Hayashi Y, Iwamoto S, et al. High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor. Pediatr Blood Cancer. 2023:e30803.
Jo T, Henzan T, Tomizawa D, Yoshihara S, Kahata K, Yamada-Fujiwara M, Okuyama Y, Shiba N, Fujii K, Umezawa Y, et al. [Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]. Rinsho Ketsueki. 2023;64(5):331-337.
van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, de Moerloose B, Dworzak MN, et al. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2023:JCO2202120.
Imai C, Sato A, Hiwatari M, Shimomura Y, Hori T, Suenobu S, Imamura T, Hara J, Hasegawa D, Takahashi H, et al. Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia. Int J Hematol. 2023.
Mark C, Meshinchi S, Joyce B, Gibson B, Harrison C, Bergmann AK, Goemans BF, Pronk CJan H, Lapillonne H, Leverger G, et al. Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. Br J Haematol. 2023.
2022
Tomizawa D. Evolution and optimization of therapies for acute lymphoblastic leukemia in infants. Int J Hematol. 2022.
Tomizawa D, Tsujimoto S-I, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, et al. A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemothe. Jpn J Clin Oncol. 2022.
2021
Tomizawa D, Miyamura T, Koh K, Ishii E. Acute lymphoblastic leukemia in infants: a quarter century of nationwide efforts in Japan. Pediatr Int. 2021.
Takachi T, Watanabe T, Miyamura T, Saito A, Deguchi T, Hori T, Yamada T, Ohmori S, Haba M, Aoki Y, et al. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene rearranged acute lymphoblastic leukemia. Blood Adv. 2021.
2020
Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AMoriya, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, et al. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer. 2020:e28692.
2019
Takachi T, Arakawa Y, Nakamura H, Watanabe T, Aoki Y, Ohshima J, Takahashi Y, Hirayama M, Miyamura T, Sugita K, et al. Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia. Int J Hematol. 2019.
2016
Endo A, Tomizawa D, Aoki Y, Morio T, Mizutani S, Takagi M. EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway. Cancer Sci. 2016.
2015
Mitsui-Sekinaka K, Imai K, Sato H, Tomizawa D, Kajiwara M, Nagasawa M, Morio T, Nonoyama S. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. J Allergy Clin Immunol. 2015.
Tomizawa D, Kato M, Takahashi H, Fujimura J, Inukai T, Fukushima T, Kiyokawa N, Koh K, Manabe A, Ohara A. Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group. Int J Hematol. 2015.